Skip to main content
. 2017 Apr 5;7:33. doi: 10.3389/fonc.2017.00033

Table 2.

Effect of immunotherapy on BM in non-small cell lung cancer trials.

Trial Treatment IDCR ICRR (%)
CheckMate 017 (47) Nivolumab 49% 19
CheckMate 012 (48) Nivolumab Not described 16.7
NCT12085070 (49) Pembrolizumab Not described 33

BM, brain metastases; IDCR, intracranial disease control rate; ICRR, intracranial response rate.